HMHaiping Mao

Haiping Mao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Haiping Mao has a total of 178 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association of 24 h Pulse Pressure Derived from Ambulatory Blood Pressure Monitoring with All-Cause and Cardiovascular Mortality in Patients Undergoing Peritoneal Dialysis: A Prospective Cohort Study

    by Jing Yu, Rui Yang, Xi Xia, Jianwen Yu, Yagui Qiu, Jianbo Li, Xiao Yang, Haiping Mao, Chunyan Yi, Qinghua Liu, et al.

    Background/Objectives: Pulse pressure (PP), an indirect hemodynamic marker reflecting the pulsatile component of blood pressure, has been linked to adverse outcomes in dialysis patients. Whether 24 h PP (24 h PP) derived from ambulatory BP monitoring (ABPM) is independently associated with all-cause and cardiovascular (CV) mortality in peritoneal dialysis (PD) patients remains unclear. Methods: This sub-cohort, nested within a single-center prospective PD database, enrolled 165 patients with baseline 24 h ABPM. The 24 h PP was analyzed continuously and in tertiles. All-cause mortality was assessed by Cox regression and CV mortality by Fine–Gray competing-risk modeling. The median follow-up was 47.4 months, counted from the date of ABPM completion. Results: During follow-up, 48 patients (29.1%) died, including 28 CV deaths (58.3% of all deaths). Per 1-SD increment in 24 h PP, the adjusted hazard ratio (HR) for all-cause mortality was 1.39 (95% confidence interval [CI] 1.03–1.87; p = 0.032), and the adjusted subdistribution hazard ratio (SHR) for CV mortality was 1.44 (95% CI 1.06–1.94; p = 0.018). The highest tertile showed elevated risks of all-cause (HR 3.47; 95% CI 1.12–10.70; p = 0.031) and CV mortality (SHR 5.11; 95% CI 1.32–19.79; p = 0.018) versus the lowest, persisting after adjustment for office PP. Conclusions: Elevated ABPM-derived 24 h PP is independently associated with increased all-cause and CV mortality in PD patients after adjustment for office PP.

  • Open Access

    The feasibility of incremental peritoneal dialysis for older patients on peritoneal dialysis

    by Ruihua Liu, Jing Guo, Hongjian Ye, Yuan Peng, Haishan Wu, Haiping Mao, Qunying Guo, Fengxian Huang, Xiao Yang

    Background: This study was performed to investigate the feasibility of incremental peritoneal dialysis (iPD) in older patients. Methods: In this retrospective cohort study, we enrolled peritoneal dialysis (PD) patients with age ≥ 60 years old at our center from 2008 to 2017. The patients were divided into two groups based on the daily PD exchanges: iPD group (≤3 × 2 L exchanges), and full dose group (≥4 × 2 L exchanges). Kaplan-Meier curves and multivariate Cox regression models were applied to evaluate the risks of anuria and mortalities between groups. Results: A total of 238 patients (186 in full dose group and 52 in iPD group) were enrolled. The mean age was 67.8 ± 5.7 years, and 45.8% were females. The baseline glomerular filtration rate was 4.15 ± 2.39 mL/min/1.73 m2 . Multivariate Cox regression models showed that patients in the iPD group patients had significantly decreased risk of anuria (hazard ratio [HR], 0.44; 95% confidence interval [CI], 0.24–0.81; p = 0.008), and all-cause mortality (HR, 0.59; 95% CI, 0.36–0.98; p = 0.04). Additionally, the incidence of peritonitis was significantly lower in the iPD group than that in the full dose group (0.115 vs. 0.197 episodes per person-year, p = 0.03) during the 36 months of PD commencement. Conclusion: Older patients with iPD were independently associated with better preservation of residual kidney function and survival outcomes. Moreover, iPD regimens are also associated with reduced incidence of peritonitis. The iPD strategy might offer a feasible option for older patients.


  • Open Access

    Trained Immunity in Bladder ILC3s Enhances Mucosal Defense Against Recurrent Urinary Tract Infections

    by Qiaoqiao Pei, Jiaqi Liu, Ziwen Tang, Jiaqing Tan, Xu Han, Xinrong Hu, Zhou Liang, Feng Li, Changjian Zhu, Ruoni Lin, et al.

    Background: Urinary tract infections (UTIs) rank among the most prevalent infectious diseases globally, with recurrent UTIs (rUTIs) posing substantial therapeutic challenges due to the lack of durable protective immunity. While trained immunity augments innate immune responses, its induction and functional significance in bladder-resident group 3 innate lymphoid cells (ILC3s) remain unknown. This study investigates whether ILC3s develop trained immunity following uropathogenic Escherichia coli (UPEC) exposure and how they contribute to mucosal defense against rUTIs. Methods: The ILC3 counts were detected in bladder sections from UTI patients and health controls (HC). A recurrent UTI mouse model was established through primary and secondary urethral UPEC inoculation. Bacterial loads in tissues were assessed, and single-cell suspensions were analyzed via flow cytometry. Bladder naïve- and UPEC-trained ILC3s were adoptively transferred, with evaluations of histopathology, epithelial barrier function, inflammation, and antimicrobial peptides. The in vitro ILC3 cell line MNK-3 was detected for IL-17A and IL-22 production following primary and secondary UPEC lysate stimulation. Results: We demonstrate that primary UPEC infection triggers ILC3 expansion in both human and murine bladders. Upon secondary challenge, these ILC3s develop trained immunity, characterized by enhanced proliferation, amplified IL-17A and IL-22 production, and improved pathogen clearance. Mechanistically, trained ILC3s reinforce urothelial barrier integrity through upregulation of antimicrobial peptides (Reg3b/Reg3g) and attenuate inflammatory pathology by suppressing pro-inflammatory cytokines (IL-6, TNF-α). Conclusions: We uncover an endogenous defense mechanism wherein UPEC primes bladder ILC3s via trained immunity, enabling amplified IL-17A- and IL-22-mediated protection against recurrent infections. These findings establish ILC3-trained immunity as a novel conceptual foundation, providing a basis for developing immunotherapies against rUTIs.


  • Open Access

    Tubule‐Derived IFN‐α Promotes GSDMD‐Mediated Macrophage Pyroptosis to Drive Renal Inflammation and Fibrosis Through JAK2/STAT2 Activation

    by Yiping Xu, Yating Wang, Siming Jiang, Yi Li, Guanglan Li, Yuchu Liu, Siyuan Li, Yiming Zhou, Qinghua Liu, Yi Zhou, et al.

    Macrophages exhibit high plasticity in response to tubular epithelial cell (TEC) injury. Gasdermin D (GSDMD)‐mediated pyroptosis amplifies the inflammatory and fibrogenic cascade, yet its role in chronic kidney disease (CKD) remains elusive. Herein, GSDMD is upregulated in kidney macrophages following unilateral renal ischemia‐reperfusion injury (UIRI) or folic acid‐induced injury, paralleling elevated pyroptosis rates. Clinically, the active fragment GSDMD‐N localizes primarily to CD68⁺ macrophages, and its renal level positively correlates with fibrosis severity across diverse CKD etiologies, reinforcing its pathogenic relevance. Macrophage‐specific deletion of Gsdmd ameliorates pyroptosis, inflammation, and renal fibrosis in both murine models, without affecting acute tubular damage in bilateral IRI. Mechanistically, injured TECs initiate this cascade through secreted IFN‐α, which activates the IFNAR1/JAK2/STAT2 axis in macrophages. STAT2 then forms a complex with IRF9, directly binding to the Gsdmd promoter to transcriptionally upregulate GSDMD expression. Genetic ablation of Jak2 , Stat2 , or Ifnar1 reduces GSDMD and GSDMD‐N levels and inhibits IL‐1β/IL‐18 secretion. Notably, administration of an IFN‐α neutralizing antibody attenuates UIRI‐induced pyroptotic macrophage, inflammation, and renal fibrosis. Collectively, the findings uncover a STAT2/IRF9‐dependent paracrine IFN‐α feedback loop that orchestrates GSDMD‐mediated pyroptosis, linking injured TECs to macrophage‐driven renal inflammation and fibrosis. Targeting this axis represents a promising strategy to halt CKD progression.


  • Open Access

    Sex-Specific Impact of Roxadustat on Residual Kidney Function in Peritoneal Dialysis Patients: A Propensity Score-Weighted Analysis

    by Simin Jiang, Guanji Zhang, Yiping Xu, Yi Li, Guanglan Li, Hongyu Li, Yuchu Liu, Siyuan Li, Jianxiong Lin, Qunying Guo, et al.


  • Open Access

    Association Between Atherogenic Index of Plasma and Clinical Outcomes in Peritoneal Dialysis Population

    by Jiayao Lan, Chunyan Yi, Ruihua Liu, Jing Guo, Shiyan Tu, Haishan Wu, Jianxiong Lin, Haiping Mao, Hongjian Ye, Wei Chen, et al.

    Background: The atherogenic index of plasma (AIP), a prognostic indicator for cardiovascular disease, has not been fully explored in relation to clinical outcomes in patients receiving peritoneal dialysis. This study aims to elucidate the relationship between baseline AIP levels and all-cause mortality, cardiovascular mortality, and the peritonitis risk in this population. Methods: This retrospective cohort study included incident peritoneal dialysis patients in our center from 1 January 2006 through 31 December 2021. The end of the follow-up time was 31 December 2023. The participants were stratified by baseline AIP levels. Kaplan–Meier curves, Cox regression analyses, and subgroup analyses were used to evaluate associations with clinical outcomes. Results: The average age of the 2460 participants in this study was 45.9 years, and 1456 (59.2%) of them were men. Diabetic nephropathy (19.5%) was the second most common kidney disease, after primary glomerulonephritis (60.8%). The higher AIP tertile group was significantly associated with increased risks of all-cause mortality, cardiovascular mortality, and peritonitis compared to the lowest AIP group, as evidenced by the Kaplan–Meier curves and the multivariate analyses. Continuous AIP levels also showed a positive correlation with the all-cause mortality and peritonitis risk, even after controlling for covariates. Conclusions: Our study highlights AIP as a predictive marker for adverse outcomes in PD patients, emphasizing its potential utility in risk stratification and clinical management.


  • Open Access

    The Association Between Atherogenic Index of Plasma and Clinical Outcomes in Peritoneal Dialysis Population

    by Jiayao Lan, Chunyan Yi, Ruihua Liu, Jing Guo, Shiyan Tu, Haishan Wu, Jianxiong Lin, Haiping Mao, Hongjian Ye, Wei Chen, et al.

    Background The atherogenic index of plasma (AIP), a prognostic indicator for cardiovascular disease, has been underexplored in relation to clinical outcomes in patients receiving peritoneal dialysis. This study aims to elucidate the relationship between baseline AIP levels and all-cause mortality, cardiovascular mortality, and peritonitis risk in this population. Methods This retrospective cohort study included incident peritoneal dialysis patients in our center from 1 January 2006 through 31 December 2021. The end of follow-up time was 31 December 2023. Participants were stratified by baseline AIP levels. Kaplan-Meier curves, Cox regression analysis, and subgroup analysis were used to evaluate associations with clinical outcomes. Results The average age of the 2,460 participants in this study was 45.9 years, and 1,456 (59.2%) of them were men. Diabetic nephropathy (19.5%) was the second most common kidney disease, after primary glomerulonephritis (60.8%). The higher AIP tertile group was statistically associated with increased risks of all-cause mortality, cardiovascular mortality, and peritonitis compared to the lowest AIP group, as evidenced by Kaplan-Meier curves and multivariate analyses. Continuous AIP levels also showed a positive correlation with all-cause mortality risk, even after controlling for covariates. Conclusion Our study highlights AIP as a predictive marker for adverse outcomes in PD patients, emphasizing its potential utility in risk stratification and clinical management.


  • Open Access

    The incidence of inflow and drain pain and associated risk factors for patients on peritoneal dialysis

    by Shun Hua, Peiyi Cao, Guanji Zhang, Guanglan Li, Simin Jiang, Yiping Xu, Jianbo Li, Jianwen Yu, Naya Huang, Jianxiong Lin, et al.

    The high prevalence and prolonged duration of inflow pain and drain pain experienced by peritoneal dialysis (PD) patients following PD catheter implantation impact their quality of life. However, there is limited data on the frequency and predisposing factors of these pains in the Chinese population undergoing peritoneal dialysis. This study encompassed individuals who underwent peritoneal dialysis catheter implantation at our institution from September 1, 2023, to March 31, 2024. Patients’ experiences of inflow pain and drain pain were evaluated using a questionnaire survey and the visual analog scale (VAS), with pain status followed up via telephone for 3 months post-surgery. A total of 141 patients were included in this study. Inflow pain occurred at rates of 56.0%, 20.9%, 16.9%, and 17.3% at 1-week, 1-month, 2-month, and 3-month postoperatively, respectively, while drain pain rates were 51.8%, 24.3%, 22.3%, and 19.5% for the same period. Slowing down the infusion rate of dialysate (57.0%) or stopping its drainage (60.3%) proved effective in reducing pain. Logistic regression analysis revealed that age (OR = 0.96, P = 0.02), gender (OR = 0.37, P = 0.03), and the method of PD catheter implantation (OR = 2.37, P = 0.04) were independent factors associated with inflow or drain pain within 1-week postoperatively. The occurrence of inflow pain and drain pain following peritoneal dialysis catheter implantation is notable. Age, gender, and the method of catheter implantation were identified as independent factors influencing the incidence of inflow or drain pain within the first postoperative week.


  • Open Access

    Gasdermin D deficiency aborts myeloid calcium influx to drive granulopoiesis in lupus nephritis

    by Jiani Shen, Feng Li, Xu Han, Dongying Fu, Yiping Xu, Changjian Zhu, Zhou Liang, Ziwen Tang, Ruilin Zheng, Xinrong Hu, et al.

    Gasdermin D (GSDMD) is emerging as an important player in autoimmune diseases, but its exact role in lupus nephritis (LN) remains controversial. Here, we identified markedly elevated GSDMD in human and mouse LN kidneys, predominantly in CD11b+ myeloid cells. Global or myeloid-conditional deletion of GSDMD was shown to exacerbate systemic autoimmunity and renal injury in lupus mice with both chronic graft-versus-host (cGVH) disease and nephrotoxic serum (NTS) nephritis. Interestingly, RNA sequencing and flow cytometry revealed that myeloid GSDMD deficiency enhanced granulopoiesis at the hematopoietic sites in LN mice, exhibiting remarkable enrichment of neutrophil-related genes, significant increases in total and immature neutrophils as well as granulocyte/macrophage progenitors (GMPs). GSDMD-deficient GMPs and all-trans-retinoic acid (ATRA)-stimulated human promyelocytes NB4 were further demonstrated to possess enhanced clonogenic and differentiation abilities compared with controls. Mechanistically, GSDMD knockdown promoted self-renewal and granulocyte differentiation by restricting calcium influx, contributing to granulopoiesis. Functionally, GSDMD deficiency led to increased pathogenic neutrophil extracellular traps (NETs) in lupus peripheral blood and bone marrow-derived neutrophils. Taken together, our data establish that GSDMD deletion accelerates LN development by promoting granulopoiesis in a calcium influx-regulated manner, unraveling its unrecognized critical role in LN pathogenesis.


  • Open Access

    Higher Platelet Count Mostly in the Normal Range Is Associated with the First Episode of Peritonitis Risk in Incident Peritoneal Dialysis Patients

    by Jing Yu, Hongjian Ye, Yi Li, Shun Hua, Jiaqi Liu, Hongyu Li, Yating Wang, Haiping Mao

    Introduction: Platelets play parts in infection and immune processes. However, the association between platelet count and the risk of peritoneal dialysis (PD)-associated peritonitis is unclear. Methods: This was a retrospective, observational, single-center cohort study. A Cox regression analysis was used to evaluate the independent association of platelet count with the occurrence of first PD-associated peritonitis. Models were adjusted for gender, age, body mass index, cardiovascular disease, diabetes mellitus, white blood cell count, neutrophil-lymphocyte ratio, hemoglobin level, albumin level, potassium level, and anti-platelet medication usage. Results: A total of 2,374 patients were enrolled in this study (59% men; mean age 47.40 ± 12.12). The average platelet count was 229.30 ± 82.12 × 109/L. 467 (20%) patients suffered from PD-associated peritonitis at least once. In the multivariable model, the adjusted hazard ratios (HRs) for quartiles 2, 3 and 4 versus quartile 1 were 1.428 (95% CI 1.060–1.924, p = 0.019), 1.663 (95% CI 1.240–2.229, p < 0.001) and 1.843 (95% CI 1.363–2.492, p < 0.001) with baseline data. A nonlinear relationship between platelet count and first PD-associated peritonitis was observed. Further, the association between platelet and first PD-associated peritonitis was significant in the patients with hypokalemia (P for interaction = 0.040). Conclusion: In PD patients, elevated platelet counts were significantly associated with an increased risk of the first onset of PD-associated peritonitis.